Company Description
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada.
The company’s commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer’s disease.
Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy.
The company was founded in 2000 and is headquartered in Vancouver, Canada.
| Country | Canada |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Michael McFadden |
Contact Details
Address: 750 West Pender Street, Suite 1200 Vancouver, BC V6C 2T8 Canada | |
| Phone | 604-564-9244 |
| Website | alphacognition.com |
Stock Details
| Ticker Symbol | ACOG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001655923 |
| ISIN Number | CA02074J5017 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Michael E. McFadden B.B.A. | Chief Executive Officer and Director |
| Lauren D'Angelo M.B.A. | Chief Operating Officer |
| Kenneth Anthony Cawkell B.A., LL.B. | Founder, Consultant, Corporate Secretary and Director |
| Henry Du C.P.A. | Vice President of Finance and Accounting and Interim Chief Financial Officer |
| Dr. Denis G. Kay M.Sc., Ph.D. | Chief Scientific Officer |
| Timothy Ayers | Head of Compliance |
| Amy Kincaid | Executive Director, Head of Marketing and Commercial Strategy |
| Jack Kelly | Executive Director and Head of Market Access |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 25, 2025 | EFFECT | Notice of Effectiveness |
| Jul 21, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jul 17, 2025 | 424B3 | Prospectus |
| Jul 8, 2025 | EFFECT | Notice of Effectiveness |
| Jul 1, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jun 23, 2025 | 8-K | Current Report |
| May 15, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 6, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2025 | DEF 14A | Other definitive proxy statements |